Richtlijn Guillain-Barré syndroom

Auteur enjaartalTripathi, 2000 B?MatevanbewijsStudietypeProspectivedoubleblind,randomlyallocatedcrossoverstudyAantalpatiëntenPatiëntenkenmerken12 Conscious GBS (22-54yrs) patients duringrecovery from themuscular weaknessand receivingpressure-supportventilation in the ICUInterventie(incl. duur,dosering)Carbamezapine(CBZ) (100 mgevery 8 hrs),3 dagenGroep 1: eerstplacebo, dan CBZGroep 2: eerstCBZ, dan placeboControle/vergelijking(incl. duur,dosering)Placebo (3 dagen)Uitkomstmaten Resultaten Overige opmerkingenPain scores (1, nopain; 5, severe pain),sedation scores (1,alert; 6, asleep, doesnot respond to verbalcommand) and totalpethidine requirementper dayGroup 1: patients, asignificant (p < .001)improvement in the sedationscore and a low requirementfor pethidine was observed 3days later, when CBZ wasstarted.Group 2: gradual increase inthe pethidine requirement anda high sedation score in laterdays of placebo medication.Tijd tussen CBZ en placebo(slechts 1 dag) te kort ?Observations also analyzedfor CBZ days vs. placebodays.Overall, the pain score (1.7 ±0.8) during the CBZ period ofboth regimens wassignificantly (p < .001) lowerversus placebo days (3.1 ±0.9). Significantly higherdoses of pethidine (3.7 ± 0.9mg/kg/day) were used on theplacebo days versus CBZdays (1.7 ± 1.0 mg/kg/day).Bewijsklassetabellen bij Multidisciplinaire richtlijn Guillain-Barré syndroom 30